Simon Peter Cooper - 13 Feb 2024 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KROS	Employee Stock Option (right to buy)	Award	$0	+40,000		$0.000000	40,000	13 Feb 2024	Common Stock	40,000	$56.18	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	25% of the shares subject to the option shall vest on February 13, 2025, and 6.25% of the shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.